Cetrorelix vs Leuprolide

Competitive GnRH receptor antagonist; immediately blocks pituitary GnRH receptors; rapidly suppresses LH/FSH without initial flare effect; used for controlled hormonal suppression

Cetrorelix is a synthetic GnRH antagonist peptide used in assisted reproductive technology (ART) to prevent premature luteinizing hormone (LH) surges during controlled ovarian stimulation protocols. By competitively blocking GnRH receptors in the pituitary gland, cetrorelix rapidly suppresses LH release without the initial hormonal flare seen with GnRH agonists, allowing more precise timing of oocyte retrieval. Clinical studies including randomized controlled trials have established cetrorelix as an effective option for LH surge prevention in IVF and ICSI cycles, with well-characterized safety and efficacy data across multiple formulations. Cetrorelix is an FDA-approved prescription medication (Cetrotide) indicated for use under specialist supervision in fertility treatment settings. Cetrorelix dosing protocols and IVF context In IVF, cetrorelix is used under two standard protocols. The multiple-dose protocol administers 0.25mg subcutaneously once daily starting from stimulation day 5 or 6, continuing until the day of oocyte trigger — this prevents LH surge during the follicular growth phase. The single-dose protocol administers 3mg once when the leading follicle reaches approximately 14mm, providing LH suppression for approximately 96 hours; a supplemental 0.25mg dose is added if trigger has not occurred by day 4. Both protocols have established efficacy data and are used depending on clinic preference and patient response characteristics. Cetrorelix vs ganirelix: Cetrorelix (Cetrotide) and ganirelix (Antagon, Orgalutran) are both GnRH receptor antagonists used in the same IVF indication. Both act as competitive antagonists at the pituitary GnRH receptor, producing rapid suppression without the initial LH flare seen with agonists. They are pharmacologically equivalent in mechanism; differences relate to proprietary formulation, dosing schedule in specific protocols, and market availability in different regions. Neither requires the weeks-long downregulation period that GnRH agonist protocols (triptorelin, leuprolide) involve — antagonist protocols can begin mid-stimulation, reducing the total cycle length. Cetrorelix and ganirelix are both prescription-only fertility medications requiring specialist reproductive endocrinology supervision.

Continuous GnRH receptor stimulation causes receptor desensitization and downregulation. This suppresses LH/FSH → testosterone/estrogen to castrate levels. Short-term pulsatile use can transiently stimulate the axis before suppression occurs.

Leuprolide (leuprorelin; Lupron) is a synthetic nonapeptide GnRH agonist (D-Leu6, des-Gly10-GnRH ethylamide) designed as a superagonist of the gonadotropin-releasing hormone receptor; paradoxically, its continuous non-pulsatile receptor occupation produces profound hypogonadotropism by causing receptor downregulation and pituitary desensitization — the opposite effect of endogenous pulsatile GnRH release — resulting in medical castration levels of sex steroids. Continuous LHRH receptor agonism initially produces a testosterone or estrogen flare before pituitary downregulation suppresses LH and FSH secretion, reducing testosterone to castrate levels in men and estrogen to postmenopausal levels in women within 2–4 weeks; this chemical hypogonadism forms the basis for its use across hormone-sensitive conditions including prostate cancer, endometriosis, uterine fibroids, and central precocious puberty. A landmark randomized controlled trial published in the New England Journal of Medicine compared leuprolide against diethylstilbestrol for metastatic prostate cancer and demonstrated equivalent efficacy with a markedly superior cardiovascular side-effect profile, establishing the pivotal evidence base that led to FDA approval and positioned GnRH agonists as the preferred hormonal therapy for prostate cancer. Leuprolide (Lupron, AbbVie; and generic formulations) is FDA-approved and requires a prescription; approved indications include advanced prostate cancer, endometriosis, uterine fibroids, central precocious puberty, and other hormone-sensitive conditions; it is available as daily subcutaneous injection, monthly depot, and multi-month depot formulations.